Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has scheduled its fourth quarter 2024 financial results announcement for March 11, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day.
The webcast will be accessible through the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay will be available at the same location approximately two hours after the call's completion and will remain accessible for at least 30 days.
Voyager Therapeutics (Nasdaq: VYGR), un'azienda biotecnologica focalizzata sui farmaci neurogenetici, ha programmato l'annuncio dei risultati finanziari del quarto trimestre 2024 per il 11 marzo 2025, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica e un webcast alle 16:30 ET dello stesso giorno.
Il webcast sarà accessibile attraverso la sezione Investitori del sito web di Voyager all'indirizzo ir.voyagertherapeutics.com. Una registrazione sarà disponibile nello stesso luogo circa due ore dopo il termine della chiamata e rimarrà accessibile per almeno 30 giorni.
Voyager Therapeutics (Nasdaq: VYGR), una empresa biotecnológica centrada en medicamentos neurogenéticos, ha programado el anuncio de sus resultados financieros del cuarto trimestre de 2024 para el 11 de marzo de 2025, después del cierre del mercado. La empresa llevará a cabo una llamada de conferencia y un webcast a las 4:30 p.m. ET el mismo día.
El webcast será accesible a través de la sección de Inversores del sitio web de Voyager en ir.voyagertherapeutics.com. Una repetición estará disponible en el mismo lugar aproximadamente dos horas después de la finalización de la llamada y permanecerá accesible durante al menos 30 días.
Voyager Therapeutics (나스닥: VYGR), 신경유전 의약품에 집중하는 생명공학 회사가 2024년 4분기 재무 결과 발표를 2025년 3월 11일 시장 종료 후에 예정했습니다. 회사는 같은 날 오후 4시 30분 ET에 컨퍼런스 콜과 웹캐스트를 개최할 것입니다.
웹캐스트는 Voyager의 웹사이트의 투자자 섹션(ir.voyagertherapeutics.com)을 통해 접근할 수 있습니다. 통화 종료 후 약 2시간 후에 동일한 위치에서 재생이 가능하며 최소 30일 동안 접근할 수 있습니다.
Voyager Therapeutics (Nasdaq: VYGR), une entreprise de biotechnologie axée sur les médicaments neurogénétiques, a prévu d'annoncer ses résultats financiers pour le quatrième trimestre 2024 le 11 mars 2025, après la fermeture du marché. L'entreprise organisera une conférence téléphonique et un webinaire le même jour à 16h30 ET.
Le webinaire sera accessible via la section Investisseurs du site Web de Voyager à l'adresse ir.voyagertherapeutics.com. Un enregistrement sera disponible au même endroit environ deux heures après la fin de l'appel et restera accessible pendant au moins 30 jours.
Voyager Therapeutics (Nasdaq: VYGR), ein Biotechnologieunternehmen, das sich auf neurogenetische Medikamente spezialisiert hat, hat die Bekanntgabe seiner finanziellen Ergebnisse für das vierte Quartal 2024 für den 11. März 2025 nach Börsenschluss angesetzt. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten.
Der Webcast wird über den Investorenbereich der Website von Voyager unter ir.voyagertherapeutics.com zugänglich sein. Eine Wiederholung wird etwa zwei Stunden nach Abschluss des Anrufs an derselben Stelle verfügbar sein und mindestens 30 Tage lang zugänglich bleiben.
- None.
- None.
LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET.
A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Media: Brooke Shenkin, brooke@scientpr.com
FAQ
When will Voyager Therapeutics (VYGR) release Q4 2024 earnings?
What time is Voyager Therapeutics (VYGR) Q4 2024 earnings call?
How can investors access VYGR's Q4 2024 earnings webcast?
How long will VYGR's Q4 2024 earnings call replay be available?
